This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vita, J. A. Articles by Keaney, J. F. Search for Related Content PubMed PubMed Citation Articles by Vita, J. A. Articles by Keaney, J. F., Jr

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1867.)
© 2001 American Heart Association, Inc.

Editorials

Hormone Replacement Therapy and Endothelial Function

The Exception That Proves the Rule?

Joseph A. Vita; John F. Keaney, Jr

From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.

Address correspondence to Joseph A. Vita, MD, Section of Cardiology, Boston Medical Center, 88 East Newton St C-818, Boston, MA 02118. E-mail jvita@bu.edu

The endothelium plays a central role in the regulation of vascular homeostasis by releasing paracrine factors that influence vascular tone, thrombosis, and inflammation in the arterial wall.¹ A principal endothelial product responsible for homeostasis is nitric oxide (NO), which is synthesized by the endothelial isoform of NO synthase² in response to a number of stimuli, including increased shear stress that accompanies increased arterial flow.³ Atherosclerosis and its risk factors are characterized by an impairment of endothelial NO-dependent vasodilation,¹ and the magnitude of this defect in the coronary circulation predicts cardiovascular disease events, raising the possibility of a pathogenic relationship.^4,5

See page 1955

This notion of a causal relation between endothelial dysfunction and cardiovascular events is also supported by intervention data. For example, lipid-lowering therapy, angiotensin-converting enzyme inhibition, smoking cessation, and exercise all reverse endothelial dysfunction and have proven benefitial against cardiovascular disease events.¹ This concordance between improved endothelial function and reduced cardiovascular events has prompted speculation that changes in endothelial function are partially responsible for the benefits.^6–8 Thus, endothelial dysfunction could potentially be used as a surrogate marker for cardiovascular disease risk in study of risk reduction therapies.³

Hormone replacement therapy has received considerable attention as a means for primary and secondary prevention of cardiovascular disease. This interest was initially based on population-based studies linking a reduced incidence of cardiovascular disease to hormone replacement therapy.^9–11 Estrogen has many potential benefits, including favorable influence on serum lipids and thrombotic factors, and there is substantial evidence that chronic estrogen treatment also improves . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Kravariti, K. K. Naka, S. N. Kalantaridou, N. Kazakos, C. S. Katsouras, A. Makrigiannakis, E. A. Paraskevaidis, G. P. Chrousos, A. Tsatsoulis, and L. K. Michalis Predictors of Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5088 - 5095. [Abstract] [Full Text] [PDF]

				S. N. Kalantaridou, K. K. Naka, E. Papanikolaou, N. Kazakos, M. Kravariti, K. A. Calis, E. A. Paraskevaidis, D. A. Sideris, A. Tsatsoulis, G. P. Chrousos, et al. Impaired Endothelial Function in Young Women with Premature Ovarian Failure: Normalization with Hormone Therapy J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3907 - 3913. [Abstract] [Full Text] [PDF]

				L. D. Kirwan, N. J. MacLusky, H. M. Shapiro, B. L. Abramson, S. G. Thomas, and J. M. Goodman Acute and Chronic Effects of Hormone Replacement Therapy on the Cardiovascular System in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1618 - 1629. [Abstract] [Full Text] [PDF]

				M. E. Widlansky, N. Gokce, J. F. Keaney Jr, and J. A. Vita The clinical implications of endothelial dysfunction J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1149 - 1160. [Abstract] [Full Text] [PDF]

				P. O. Bonetti, L. O. Lerman, and A. Lerman Endothelial Dysfunction: A Marker of Atherosclerotic Risk Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 168 - 175. [Abstract] [Full Text] [PDF]

				D. R. Bell, K. E. Gochenaur, and J. Hecht O2--mediated impairment of coronary arterial relaxation is prevented by overnight treatment with 1 nM beta -estradiol J Appl Physiol, December 1, 2002; 93(6): 1952 - 1958. [Abstract] [Full Text] [PDF]